---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-21-000521"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:18:54.707277+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q3 net loss $1.1M; revenue $6.0M, 9% sequential growth

## Summary
- Net revenue $6.0M, 9% sequential growth; adjusted net revenue up 9% YoY excluding prior year inventory stocking.
- Net loss $1.1M ($0.02 per share) vs net income $0.2M ($0.01) in Q3 2020.
- Gross margin 57.9%, down from 64.8% due to manufacturing transition delays and scrap reserve.
- Received FDA 510(k) clearance for Hizentra 20ml prefilled syringe with Freedom Edge system.
- Three leadership hires and strategic plan update scheduled for December 2, 2021.

## SEC filing metadata
- accession: 0001161697-21-000521
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169721000521/0001161697-21-000521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169721000521/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-21-000521
- JSON: https://secwatch.observer/filing/0001161697-21-000521.json
- Plain text: https://secwatch.observer/filing/0001161697-21-000521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.